SOL Capital Management’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.82M | Sell |
21,990
-8,052
| -27% | -$668K | 0.18% | 124 |
|
|
2025
Q1 | $2.44M | Sell |
30,042
-842
| -3% | -$68.3K | 0.27% | 96 |
|
|
2024
Q4 | $2.78M | Sell |
30,884
-1,221
| -4% | -$110K | 0.31% | 89 |
|
|
2024
Q3 | $3.17M | Buy |
32,105
+165
| +0.5% | +$16.3K | 0.35% | 78 |
|
|
2024
Q2 | $2.96M | Buy |
31,940
+174
| +0.5% | +$16.1K | 0.36% | 78 |
|
|
2024
Q1 | $3.01M | Buy |
31,766
+7,570
| +31% | +$718K | 0.38% | 80 |
|
|
2023
Q4 | $2.16M | Buy |
24,196
+13,865
| +134% | +$1.24M | 0.29% | 100 |
|
|
2023
Q3 | $754K | Buy |
10,331
+4,368
| +73% | +$319K | 0.12% | 168 |
|
|
2023
Q2 | $496K | Buy |
5,963
+1,078
| +22% | +$89.7K | 0.08% | 203 |
|
|
2023
Q1 | $372K | Buy |
4,885
+350
| +8% | +$26.7K | 0.06% | 228 |
|
|
2022
Q4 | $376K | Buy |
4,535
+895
| +25% | +$74.3K | 0.07% | 218 |
|
|
2022
Q3 | $289K | Buy |
3,640
+290
| +9% | +$23K | 0.06% | 225 |
|
|
2022
Q2 | $249K | Buy |
3,350
+600
| +22% | +$44.6K | 0.05% | 234 |
|
|
2022
Q1 | $247K | Buy |
2,750
+850
| +45% | +$76.3K | 0.04% | 243 |
|
|
2021
Q4 | $213K | Buy |
1,900
+200
| +12% | +$22.4K | 0.04% | 249 |
|
|
2021
Q3 | $214K | Hold |
1,700
| – | – | 0.04% | 237 |
|
|
2021
Q2 | $230K | Hold |
1,700
| – | – | 0.05% | 238 |
|
|
2021
Q1 | $231K | Hold |
1,700
| – | – | 0.05% | 225 |
|
|
2020
Q4 | $239K | Buy |
+1,700
| New | +$239K | 0.06% | 216 |
|